Conatus Pharmaceuticals, Inc. (CNAT)

Conatus-Pharma-logoConatus Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes novel medicines for the treatment of liver disease. Conatus develops emracasan, the company’s lead compound for treating patients suffering from chronic liver disease, as well as acute exacerbations of chronic liver disease. An orally active pan-caspase protease inhibitor, emracasan is designed for reduction of the activity of ten human caspases, the enzymes mediating inflammation and death of cells, or apoptosis.

The company believes that emracasan has the capability to interrupt the progress of liver disease, and can provide options for treatment in various areas of liver disease based on the preclinical and clinical trial results suggesting that emracasan has the potential to slow the progression of liver disease, regardless of its original cause. Emracasan has been studied in ten clinical trials with more than 500 subjects.

In the Phase 2b of clinical trial in liver disease patients, emracasan has demonstrated a consistent, rapid, significant, and sustained reduction of elevated levels of alanine aminotransferase (ALT) and cleaved Cytokeratin 18 (cCK18), the two key biomarkers of cell death and inflammation that are implicated in the progression and severity of liver disease.

Conatus Pharmaceuticals, Inc. has designed a clinical program demonstrating emracasan’s therapeutic benefits across the spectrum of fibrotic liver disease. The company’s strategy focuses on targeting of indications for emracasan in small patient populations, including the small population of patients with chronic liver failure (CLF), and acute-on-chronic liver failure (ACLF).

Conatus Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNAT. The company is committed to serving the best interests of their shareholders. They provide key shareholder information and financial reports to help put the company’s financial performance into perspective.

Yahoo! Finance: CNAT News

Latest Financial News for CNAT

How Long Will Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) Cash Last?

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) continues its loss-making streak, announcing negative earnings for its...

Top Ranked Momentum Stocks to Buy for September 10th

Top Ranked Momentum Stocks to Buy for September 10th

Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know

Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?